Literature DB >> 15373969

Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells.

Ann Marshak-Rothstein1, Liliana Busconi, Christina M Lau, Abigail S Tabor, Elizabeth A Leadbetter, Shizuo Akira, Arthur M Krieg, Grayson B Lipford, Gregory A Viglianti, Ian R Rifkin.   

Abstract

Synthetic single-stranded oligodeoxynucleotides (15-30 bp) containing CpG motifs and phosphorothioate backbones (CpG s-ODN), immune complexes consisting of anti-nucleosome mAbs and mammalian chromatin (chromatin IC), and immune complexes consisting of anti-hapten mAbs and haptenated-double stranded DNA fragments ( approximately 600 bp) can all effectively stimulate transgenic B cells expressing a rheumatoid factor receptor by a TLR9-dependent process. However, differential sensitivity to both s-ODN and small molecule inhibitors suggests that stimulatory CpG sODN and chromatin IC may either access TLR9 via different routes or depend on discrete activation parameters. These data have important implications regarding the therapeutic application of TLR9 inhibitors to the treatment of systemic autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15373969     DOI: 10.1179/096805104225005850

Source DB:  PubMed          Journal:  J Endotoxin Res        ISSN: 0968-0519


  12 in total

Review 1.  Manifold mechanisms of Toll-like receptor-ligand recognition.

Authors:  Ken J Ishii; Cevayir Coban; Shizuo Akira
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

Review 2.  Modulation of toll-like receptor signaling by antimicrobial peptides.

Authors:  Ernest Y Lee; Michelle W Lee; Gerard C L Wong
Journal:  Semin Cell Dev Biol       Date:  2018-02-12       Impact factor: 7.727

3.  The role of immunostimulatory nucleic acids in septic shock.

Authors:  Farag Bleiblo; Paul Michael; Danielle Brabant; Chilakamarti V Ramana; Tc Tai; Mazen Saleh; Joseph E Parrillo; Anand Kumar; Aseem Kumar
Journal:  Int J Clin Exp Med       Date:  2012-01-15

4.  RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes.

Authors:  Ana M Avalos; Kerstin Kiefer; Jane Tian; Sean Christensen; Mark Shlomchik; Anthony J Coyle; Ann Marshak-Rothstein
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

5.  The regulation of autoreactive B cells during innate immune responses.

Authors:  Barbara J Vilen; Jennifer A Rutan
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  Anti-chromatin antibodies drive in vivo antigen-specific activation and somatic hypermutation of rheumatoid factor B cells at extrafollicular sites.

Authors:  Robin A Herlands; Jacqueline William; Uri Hershberg; Mark J Shlomchik
Journal:  Eur J Immunol       Date:  2007-12       Impact factor: 5.532

7.  Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells.

Authors:  Kristina E Halcomb; Sandirai Musuka; Toni Gutierrez; Heather L Wright; Anne B Satterthwaite
Journal:  Mol Immunol       Date:  2008-10-11       Impact factor: 4.407

8.  Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha.

Authors:  Melissa B Uccellini; Liliana Busconi; Nathaniel M Green; Patricia Busto; Sean R Christensen; Mark J Shlomchik; Ann Marshak-Rothstein; Gregory A Viglianti
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

9.  Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus.

Authors:  Sean R Christensen; Michael Kashgarian; Lena Alexopoulou; Richard A Flavell; Shizuo Akira; Mark J Shlomchik
Journal:  J Exp Med       Date:  2005-07-18       Impact factor: 14.307

10.  RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement.

Authors:  Christina M Lau; Courtney Broughton; Abigail S Tabor; Shizuo Akira; Richard A Flavell; Mark J Mamula; Sean R Christensen; Mark J Shlomchik; Gregory A Viglianti; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  J Exp Med       Date:  2005-10-31       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.